NCT/Study#
NCT06171685 /
MMRC-099
MMRC Horizon One: A Phase II Randomized adaptive platform Trial evaluating novel therapies in relapsed or refractory multiple myeloma
DISEASE GROUP:
Multiple Myeloma
current phase:
Phase II
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
